Niagen Bioscience
NAGE
59 hedge funds and large institutions have $19.1M invested in Niagen Bioscience in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 10 closing their positions.
673% more call options, than puts
Call options by funds: $232K | Put options by funds: $30K
27% more capital invested
Capital invested by funds: $15M → $19.1M (+$4.05M)
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
2.64% less ownership
Funds ownership: 17.91% → 15.27% (-2.6%)
5% less funds holding
Funds holding: 62 → 59 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$744K |
| 2 |
Millennium Management
New York
|
+$733K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$599K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$149K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$127K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YRHAM
Yong Rong (HK) Asset Management
Sheung Wan,
Hong Kong
|
-$2.38M |
| 2 |
Barclays
London,
United Kingdom
|
-$307K |
| 3 |
E
Ergoteles
New York
|
-$160K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$118K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$94K |
NAGE Hedge Fund Activity: Q4 2022 in Review
59 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q4 2022, worth a combined $19.1M — up 27% from $15M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of NAGE and 7 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 18 added.
The largest buyer was Tieton Capital Management, adding an estimated $744K. The largest seller was Yong Rong (HK) Asset Management, exiting entirely with an estimated $2.38M sold.
- 59 institutional investors held Niagen Bioscience (NAGE) as of Q4 2022, down from 62 in Q3 2022.
- Funds reported $19.1M of Niagen Bioscience stock for Q4 2022, up 27% quarter-over-quarter.
- 7 funds opened new Niagen Bioscience positions in Q4 2022 and 10 closed out, a net change of -3 holders.
- The largest Niagen Bioscience buyer in Q4 2022 was Tieton Capital Management, an estimated $744K added.
- The largest Niagen Bioscience seller in Q4 2022 was Yong Rong (HK) Asset Management, an estimated $2.38M sold.
Based on aggregated 13F filings for Q4 2022.